TMS for Panic Disorder
TMS is not currently recommended as a first-line treatment for panic disorder, but may be considered as an experimental option for treatment-resistant cases, with the most evidence supporting high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC) for 4+ weeks.
Current Evidence Status
The evidence base for TMS in panic disorder remains limited and inconsistent. The most recent Brazilian Psychiatric Association guidelines for panic disorder (2025) do not include TMS as a recommended intervention, instead endorsing SSRIs, SNRIs, TCAs, and CBT as first-line treatments 1. This absence from current guidelines reflects the weak and contradictory research evidence.
Research Evidence Quality
A 2019 systematic review examining pharmacological and neuromodulatory treatments for panic disorder found that TMS demonstrated efficacy in only one of two randomized controlled trials 2. The meta-analysis by Cirillo et al. (2019) could not draw firm conclusions about TMS for panic disorder due to insufficient studies and sample sizes 3. The 2026 systematic review similarly noted that few studies have evaluated TMS for panic disorder, preventing definitive conclusions 4.
When to Consider TMS (Treatment-Resistant Cases Only)
TMS should only be considered when:
- Patient has failed adequate trials of first-line SSRIs/SNRIs
- CBT has been unsuccessful or unavailable
- Comorbid major depression is present (where TMS has stronger evidence)
- Patient cannot tolerate or refuses standard pharmacotherapy
Recommended Protocol (Based on Available Evidence)
Target: Left dorsolateral prefrontal cortex (DLPFC) 5, 6
Parameters:
- Frequency: High-frequency (10-20 Hz) stimulation over left DLPFC 5
- Duration: Minimum 4 weeks of treatment 2
- Sessions: 20 sessions over 1 month (typically 5 sessions/week) 5
- Intensity: 110% of resting motor threshold 7
The 2018 study by Mantovani et al. showed a 38% reduction in Panic Disorder Severity Scale scores with this protocol in treatment-resistant patients with comorbid depression 5.
Alternative Protocols with Weaker Evidence
An older protocol using low-frequency (1 Hz) stimulation over right DLPFC showed only modest, clinically non-relevant improvement 7. Sequential bilateral stimulation (alternating right and left DLPFC) also failed to produce meaningful benefits 7.
Critical Limitations and Caveats
- No evidence for remission: Studies have not demonstrated that TMS produces remission in panic disorder 4
- Small sample sizes: Most studies involve fewer than 15 patients 2, 5, 6
- Short follow-up: Few studies report outcomes beyond 12 weeks 4
- High risk of bias: Many trials have methodological limitations 4
- Unclear if panic symptoms improve independently: In the comorbid depression study, panic and depression improvements were not significantly correlated, raising questions about mechanism 5
Safety Profile
TMS appears well-tolerated with no difference in serious adverse events compared to sham 4. Common side effects include scalp discomfort and mild headaches, particularly with accelerated protocols 8.
Clinical Bottom Line
Given the weak evidence base, TMS should be positioned as an experimental intervention for panic disorder, reserved for treatment-resistant cases where standard evidence-based treatments have failed. The strongest available protocol involves high-frequency left DLPFC stimulation for at least 4 weeks, though even this approach lacks robust support from multiple high-quality trials. Patients should be counseled that response rates are uncertain and that first-line treatments (SSRIs, SNRIs, CBT) remain the standard of care 1.